Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

Study Summary

This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).

Conditions

Chronic Inducible Urticaria Chronic Spontaneous Urticaria

Interventions / Drugs

BLU-808 Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment105 participants

Primary Completion—

Lead SponsorBlueprint Medicines Corporation

Data Retrieved2026-04-11 04:08:23.597164+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.